| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SGEN | Common Stock | Sale | $1,827,427 | -8,567 | -17% | $213.31 | 42,792 | 09 Nov 2023 | Direct | F1, F2, F3 |
| transaction | SGEN | Common Stock | Sale | $46,626 | -218 | -0.51% | $213.88 | 42,574 | 09 Nov 2023 | Direct | F1, F3 |
| holding | SGEN | Common Stock | 119,471 | 09 Nov 2023 | by Trust |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a written plan, entered into on November 29, 2022, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). |
| F2 | Reflects sales of common stock executed in multiple transactions at prices ranging from $212.79 to $213.72. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |
| F3 | Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. |